Publication | Closed Access

A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect

VaccinationNovel Therapeutic VaccineHuman Papillomavirus VaccinesVaccine TargetAntitumor EffectImmunologyTherapeutic VaccineCd4 T Cell ResponsesVaccine DesignImmunotherapyMedicineRadiation OncologyE6/e7 Fusion ProteinCancer-associated Virus